As of Feb 05
| -0.01 / -0.12%|
The 1 analysts offering 12-month price forecasts for Ocata Therapeutics Inc have a median target of 8.50, with a high estimate of 8.50 and a low estimate of 8.50. The median estimate represents a +0.47% increase from the last price of 8.46.
The current consensus among 3 polled investment analysts is to Hold stock in Ocata Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.